Search Results

Deals

Great Point Partners Acquires Lyocontract GmbH, Germany-Based Drug Product CDMO

Great Point Partners, a Greenwich-based investment firm focused exclusively on the health care industry, announced the acquisition of Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization based in Ilsenburg, Germany.

June 13, 2024

·

3 min read

Business

Oakwood Chemical Announces Strategic Partnership with EMP Biotech GmbH

Oakwood Chemical is thrilled to unveil its collaboration with EMP Biotech GmbH, a move set to streamline the oligo synthesis supply chain.

April 9, 2024

·

2 min read

Press Releases

FGK Clinical Research GmbH Highlights 3.5 Years of Success with Flex Databases

October 10, 2024

·

1 min read

Drug Development

HD Immune GmbH Foundation and Publication of Latest Pre-Clinical Data

HD Immune GmbH announces commencement of operations by its two founders Dr. Stefan Bartl and Dr. Lionel Wightman.

January 23, 2024

·

2 min read

Press Releases

Dovetail Genomics and Goenomics GmbH Announce Strategic Partnership to Enhance Genome Annotation Services

August 21, 2024

·

4 min read

Press Releases

BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations

August 15, 2024

·

3 min read

Business

UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers

UroGen Pharma Ltd. today announced a licensing agreement with medac GmbH to develop a next-generation novel mitomycin-based formulation for urothelial cancers.

January 17, 2024

·

6 min read

News

New4med GmbH Announces First Cases of its novel Basivertebral Nerve Ablation (BVNA)

July 8, 2024

·

2 min read

Drug Development

Hummingbird Diagnostics GmbH to Unveil Pioneering Alzheimer’s Disease Biomarker Research at CTAD Conference

Hummingbird Diagnostics GmbH today announced the presentation of groundbreaking research data at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in Boston.

October 25, 2023

·

2 min read

Pharm Country

NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity

NanoVibronix, Inc. (NASDAQ: NAOV) today announced that it has entered into a non-binding letter of intent (the “LOI”) with APOGEPHA Arzneimittel GmbH (“APOGEPHA”) in which both parties will analyze the potential for APOGEPHA to distribute NanoVibronix’s premiere UroShield product in Germany and other European markets.

December 4, 2023

·

4 min read